金准生物，量子点，炎症二联检

[Product Name]Respiratory Virus (5-in-1) IgM Antibody Test Kit

[Sample Type]serum, plasma or whole blood

[Intended Use]
For the in vitro qualitative detection of Respiratory Syncytial Virus (RSV) IgM antibody, Adenovirus IgM antibody, Coxsackie virus IgM antibody, Human parvovirus B19 IgM antibody, and Paramyxovirus parotitis (Mumps virus) IgM antibody in human serum, plasma, or whole blood samples.

[Clinical Department]
Clinical Laboratory, Paediatrics Department, Emergency Department, Respiratory Medicine Department, Infectious Diseases Department, Outpatient Department, Cardiology Department, Dermatology Department, Rheumatology and Immunology Department, etc.

Product Parameters
Item	Respiratory Virus (5-in-1) IgM Ab (Immunochromatography)
Test Time	15-20min
Sample Type	serum, plasma or whole blood
Sensitivity	/
Storage Condition	4-30℃
Packing Specification	1 Test/Kit; 2 Tests/Kit; 5 Tests/Kit; 10 Tests/Kit; 20 Tests/Kit; 40 Tests/Kit

RSV, ADV, CV, B19V and MuV are common clinical respiratory viruses. Infection is mostly characterised by respiratory symptoms, while some cases may lead to extrapulmonary complications.

RSV IgM antibodies emerge 2–7 days post-infection and start to decline between days 8 and 40, serving clinically as a key indicator for early RSV infection.

ADV IgM antibodies appear approximately one week, indicating a recent or acute infection status.

CV IgM antibodies rise rapidly from the first week of infection and decline or disappear within 3–4 weeks, which is clinically recognised as one of the important indicators for diagnosing acute or persistent infections.

B19V IgM antibodies can be detected around days 7–10 post-infection. This antibody signals a recent or acute infection and also acts as a critical indicator for antenatal monitoring.

MuV IgM antibodies appear on the 7th day post-infection, peak within 2 weeks, and can persist for several months.

1. It improves the aetiological diagnosis rate of acute respiratory tract infections and reduces the incidence of missed and misdiagnoses.

2. It assists in determining the infection course and disease severity.

3. It provides pivotal support for the precise diagnosis and treatment of infections in high-risk susceptible groups, including infants, young children, the elderly, pregnant women, and immunocompromised individuals.

Number	Controls	Number of registration certificate
1	降钙素原质控品（Procalcitonin（PCT）Control）	粤械注准 20172400844
2	白介素6质控品（Interleukin-6（IL-6）Control）	粤械注准 20172400852
3	C反应蛋白质控品（C-Reactive Rrotein（CRP）Control）	粤械注准 20172400847
4	心肌肌钙蛋白 I 质控品（Cardiac Troponin I（cTnl）Control）	粤械注准 20172400846
5	肌酸激酶同工酶质控品（Creatine kinase Isoenzyme-MB（CK-MB）Control）	粤械注准 20172400849
6	D · 二聚体制控品（D-Dimer Control）	粤械注准 20172400843
7	人心型脂肪酸结合蛋白质控品（Human Heart-type Fatty Aeid Binding Rrotein（H-FABP）Control）	粤械注准 20172400851
8	肌红蛋白质控品（Myoglobin（MYO）Control）	粤械注准 20172400848
9	N末端脑钠肱前体质控品（N-terminal pro-B-type natriuretic peptide（NT-proBNP）Control）	粤械注准 20172400845
10	中性粒细胞明胶酶相关脂质运载蛋白质控品（Neutrophil gelatinase-assoiated lipocalin（NGAL）Control）	粤械注准 20172400850